Skip to main content

Kyowa Hakko Kirin Value Stock - Dividend - Research Selection

Kyowa Hakko Kirin Co., Ltd.

ISIN: JP3256000005, WKN: 858523

Market price date: 15.01.2021
Market price: 2.818,00 JPY




Kyowa Hakko Kirin Co., Ltd. Fundamental data and company key figures of the share

Annual reports in JPY
Key figures 09-02-2020
Cash flow
Net operating cash flow 53.655.000.000
Capital Expenditures -7.030.000.000
Free cash flow 46.625.001.472
Balance sheet
Total Equity 678.250.000.000
Liabilities & Shareholders equity 784.453.000.000
Income statement
Net income 67.084.000.000
Eps (diluted) 124,566
Diluted shares outstanding 538.542.000
Net sales/revenue 305.820.000.000

Fundamental ratios calculated on: 15-01-2021

Ratios
Key figures 15-01-2021
Cash flow
P/C 28,29
   
P/FC 32,55
Balance sheet
ROI8,55
ROE86,46
Income statement
P/E22,62
Div. Yield0,00%
P/B2,24
P/S4,96


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol4151.TSE
Market Capitalization14.631.528.448,00 USD
CountryJapan
IndicesNIKKEI 225
SectorsPharma
Raw Data SourceIFRS in Millionen JPY
Stock Split
Internetwww.kyowa-kirin.co.jp


Description of the company

Kyowa Hakko Kirin Co., Ltd. mainly deals with medical products and biochemical companies. The Medical Devices segment is engaged in the manufacture, sale and promotion of ethical agents and reagents for clinical trials, the development of candidate drugs for new drugs, and the discovery and development of antibody drug manufacturing technologies. She also worked in the contracting, retail and wholesale and insurance agencies. The Biochemistry segment manufactures and sells medical and industrial materials, mainly amino acids and nucleic acids, as well as health products. This segment also designs and builds facilities. As of December 31, 2013, 47 subsidiaries, three associated companies and one parent company were involved.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.kyowa-kirin.co.jp